Elanco (ELAN) Faces Securities Class Action Lawsuit Over Alleged Safety Risks of Zenrelia – Hagens Berman

SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Animal health company Elanco (ELAN) and its most senior executives are the targets of a securities class action suit, alleging that they downplayed potential safety concerns related to Elanco’s new oral Janus kinase inhibitor, Zenrelia, while overstating its prospects for a rapid U.S. market entry. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 ...